An NBC News investigation published on August 27, 2026 has found that the United States lacks a comprehensive national system for tracking adverse events associated with peptides, leaving significant gaps in safety surveillance as peptide use expands well beyond FDA-approved GLP-1 drugs.
The investigation examined who is monitoring adverse effects of peptides in the U.S. and found that, in many cases, no one is. The report highlights that even allowing compounding pharmacies to produce certain peptides would not provide the level of oversight that some experts say is necessary.
The findings come at a time of growing consumer interest in peptides for a range of uses, including products marketed outside the FDA approval process.
What happened
NBC News published an investigation examining the landscape of peptide safety monitoring in the United States. The report found that there is no comprehensive national system for tracking adverse events tied to peptides.
According to the investigation, gaps in federal and state adverse event surveillance extend beyond FDA-approved GLP-1 drugs to include compounded and research-grade peptide products. The report notes that permitting compounding pharmacies to manufacture certain peptides still would not deliver the oversight that some experts argue is needed.
The investigation surfaces gaps in federal and state adverse event surveillance for peptides, which experts say could leave some adverse events unreported and unexamined.
Why it matters
As peptide use grows beyond approved GLP-1 medications into research-grade and compounded products, the absence of a robust national tracking system means adverse events may go undetected. Consumers using non-approved peptides have limited safety data available to inform their decisions.
The investigation’s findings could inform future regulatory or legislative action on peptide safety surveillance. The report may increase pressure on the U.S. Department of Health and Human Services or the FDA to formalize adverse event reporting requirements for compounding pharmacies.
Several groups are potentially affected by the surveillance gaps identified in the report, including peptide consumers, compounding pharmacies, telehealth prescribers, the FDA, state pharmacy boards, and policymakers.
What to watch next
- Whether HHS or FDA responds to the investigation with proposed changes to adverse event reporting requirements for compounding pharmacies
- Whether state pharmacy boards move to strengthen peptide adverse event tracking at the state level
- Whether congressional lawmakers cite the investigation in calls for legislative action on peptide safety surveillance
- How compounding pharmacies and telehealth prescribers adjust practices in response to heightened scrutiny
Sources
NBC News — Investigation on peptide adverse event monitoring gaps
Industry information only. Not medical or legal advice.
